PERSONALIZED THERAPEUTIC STRATEGIES.
Personalized Therapies
Throughout the last couple of years the trend in cancer treatment is to abandon expensive and ineffective standard therapy concepts and to focus on approaches which are well adjusted to individual patients’ needs. Decisions about individual therapeutics and treatment strategies are based on the genetic and cellular features of the tumor. This approach not only has beneficial socio-economic consequences in terms of costs and quality of life, but also increases life expectancy and recovery prospects of cancer patients.
Competence platform north and south of the Brenner
Strong competences in various areas of personalized cancer medicine have evolved in this region during the last couple of years. Aiming to build a competence platform, scientific and clinical partners have joined forces by forming a supra-regional consortium. The overall project budget amounts to 1.3 million euros, more than 1 million of which are grants from the ERDF (European Regional Development Fund).
Perfect tools for efficacy assessments of therapeutics
Driven by precision medicine, the relevance of tumor organoids is constantly increasing. Tumor organoids are 3-dimensional cell complexes, gained from tumor samples or biopsies, and cultivated in test tubes. Through optimized technologies they can be quickly cultivated and preserve nearly all of the features from the original tumor. Therefore, they allow genotyping of the tumor and, moreover, the sensitivity of the tumor to specific therapeutics can be assessed. This approach spares patients from side effects caused by medicine which don’t have any beneficial effect for their treatment.
PreCanMed is funded by the EU, the ERDF, and the program Interreg V-A Italy-Austria 2014-2020.
Volume: 1.3 million Euro
Duration: 03/2017 – 02/2021
Project partners:
- LNCIB Laboratorio Nazionale del Consorzio Interuniversitario delle Biotecnologie Area di Ricerca
- UNITS Universita degli studi di Triest
- UNIUD Universita degli studi di Udine
- ADSI Austrian Drug Screening Institute GmbH
- MUI Medizinische Universität Innsbruck
News: